Eklund EA, Orgard M, Wallin D, Sayin SI, et al. Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients: addition of durvalumab to combined chemoradiotherapy improves survival. Lung Cancer 2025;204:108573.
PMID: 40349418